The compendium of newly emerging and currently available hemophilia and anticoagulant treatments, while offering new choices for improved patient care, can create significant levels of interference with routine and specialized laboratory coagulation assays. Our new educational session will examine the interference in coagulation tests from presence of the direct oral anticoagulants (DOACs) and the extended half-life (EHL) and non-factor products. It is important for laboratories to be aware of how both classes of these products, when present, can impact downstream results and clinical decision making.
Upon completion of this session participants will be able to:
1. Identify how to detect DOAC’s with routine coagulation tests and how they impact results.
2. Understand how the new EHL products for hemophilia A and B perform in relation to the laboratory’s coagulation reagents.
3. Increase awareness of the impact of these issues on coagulation testing.